The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Cell and Gene Therapy Manufacturing Services Market Research Report 2025

Global Cell and Gene Therapy Manufacturing Services Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1799726

No of Pages : 111

Synopsis
Gene therapy aims to treat disorders by replacing or introducing genes into cells— either inside the body (in vivo) or outside of the body (ex vivo).
Global Cell and Gene Therapy Manufacturing Services market is projected to reach US$ 8643.5 million in 2029, increasing from US$ 4729.8 million in 2022, with the CAGR of 8.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Cell and Gene Therapy Manufacturing Services market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Cell and Gene Therapy Manufacturing Services market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Thermo Fisher Scientific
Merck KGaA
Charles River Laboratories
Lonza
Catalent
WuXi AppTec
Takara Bio Inc
Nikon Corporation
FUJIFILM Holdings Corporation
F. Hoffmann-La Roche
Oxford Biomedica Plc
Cell and Gene Therapy Catapult
The Discovery Labs LLC
RoslinCT
JRS PHARMA
FinVector
ABL
Resilience
BioCentriq
Porton Biopharma Limited
Andelyn Biosciences
Commercializing Living Therapies
Vibalogics
Anemocyte Srl
ElevateBio
Segment by Type
By Cell Therapy
Allogeneic
Autologous
Viral Vector
By Gene Therapy
Non-viral Vector
Oligonucleotides
Viral Vector
Virus Vector
Segment by Application
Oncology Diseases
Cardiovascular Diseases
Orthopedic Diseases
Ophthalmology Diseases
Infectious Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Cell and Gene Therapy Manufacturing Services report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis By Cell Therapy
1.2.1 Global Cell and Gene Therapy Manufacturing Services Market Size Growth Rate By Cell Therapy: 2018 VS 2022 VS 2029
1.2.2 Allogeneic
1.2.3 Autologous
1.2.4 Viral Vector
1.3 Market by Application
1.3.1 Global Cell and Gene Therapy Manufacturing Services Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Oncology Diseases
1.3.3 Cardiovascular Diseases
1.3.4 Orthopedic Diseases
1.3.5 Ophthalmology Diseases
1.3.6 Infectious Diseases
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cell and Gene Therapy Manufacturing Services Market Perspective (2018-2029)
2.2 Cell and Gene Therapy Manufacturing Services Growth Trends by Region
2.2.1 Global Cell and Gene Therapy Manufacturing Services Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cell and Gene Therapy Manufacturing Services Historic Market Size by Region (2018-2023)
2.2.3 Cell and Gene Therapy Manufacturing Services Forecasted Market Size by Region (2024-2029)
2.3 Cell and Gene Therapy Manufacturing Services Market Dynamics
2.3.1 Cell and Gene Therapy Manufacturing Services Industry Trends
2.3.2 Cell and Gene Therapy Manufacturing Services Market Drivers
2.3.3 Cell and Gene Therapy Manufacturing Services Market Challenges
2.3.4 Cell and Gene Therapy Manufacturing Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cell and Gene Therapy Manufacturing Services Players by Revenue
3.1.1 Global Top Cell and Gene Therapy Manufacturing Services Players by Revenue (2018-2023)
3.1.2 Global Cell and Gene Therapy Manufacturing Services Revenue Market Share by Players (2018-2023)
3.2 Global Cell and Gene Therapy Manufacturing Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cell and Gene Therapy Manufacturing Services Revenue
3.4 Global Cell and Gene Therapy Manufacturing Services Market Concentration Ratio
3.4.1 Global Cell and Gene Therapy Manufacturing Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell and Gene Therapy Manufacturing Services Revenue in 2022
3.5 Cell and Gene Therapy Manufacturing Services Key Players Head office and Area Served
3.6 Key Players Cell and Gene Therapy Manufacturing Services Product Solution and Service
3.7 Date of Enter into Cell and Gene Therapy Manufacturing Services Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell and Gene Therapy Manufacturing Services Breakdown Data by Type
4.1 Global Cell and Gene Therapy Manufacturing Services Historic Market Size by Type (2018-2023)
4.2 Global Cell and Gene Therapy Manufacturing Services Forecasted Market Size by Type (2024-2029)
5 Cell and Gene Therapy Manufacturing Services Breakdown Data by Application
5.1 Global Cell and Gene Therapy Manufacturing Services Historic Market Size by Application (2018-2023)
5.2 Global Cell and Gene Therapy Manufacturing Services Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Cell and Gene Therapy Manufacturing Services Market Size (2018-2029)
6.2 North America Cell and Gene Therapy Manufacturing Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Cell and Gene Therapy Manufacturing Services Market Size by Country (2018-2023)
6.4 North America Cell and Gene Therapy Manufacturing Services Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cell and Gene Therapy Manufacturing Services Market Size (2018-2029)
7.2 Europe Cell and Gene Therapy Manufacturing Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Cell and Gene Therapy Manufacturing Services Market Size by Country (2018-2023)
7.4 Europe Cell and Gene Therapy Manufacturing Services Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cell and Gene Therapy Manufacturing Services Market Size (2018-2029)
8.2 Asia-Pacific Cell and Gene Therapy Manufacturing Services Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Cell and Gene Therapy Manufacturing Services Market Size by Region (2018-2023)
8.4 Asia-Pacific Cell and Gene Therapy Manufacturing Services Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cell and Gene Therapy Manufacturing Services Market Size (2018-2029)
9.2 Latin America Cell and Gene Therapy Manufacturing Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Cell and Gene Therapy Manufacturing Services Market Size by Country (2018-2023)
9.4 Latin America Cell and Gene Therapy Manufacturing Services Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Size (2018-2029)
10.2 Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Size by Country (2018-2023)
10.4 Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Detail
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Cell and Gene Therapy Manufacturing Services Introduction
11.1.4 Thermo Fisher Scientific Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Merck KGaA
11.2.1 Merck KGaA Company Detail
11.2.2 Merck KGaA Business Overview
11.2.3 Merck KGaA Cell and Gene Therapy Manufacturing Services Introduction
11.2.4 Merck KGaA Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.2.5 Merck KGaA Recent Development
11.3 Charles River Laboratories
11.3.1 Charles River Laboratories Company Detail
11.3.2 Charles River Laboratories Business Overview
11.3.3 Charles River Laboratories Cell and Gene Therapy Manufacturing Services Introduction
11.3.4 Charles River Laboratories Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.3.5 Charles River Laboratories Recent Development
11.4 Lonza
11.4.1 Lonza Company Detail
11.4.2 Lonza Business Overview
11.4.3 Lonza Cell and Gene Therapy Manufacturing Services Introduction
11.4.4 Lonza Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.4.5 Lonza Recent Development
11.5 Catalent
11.5.1 Catalent Company Detail
11.5.2 Catalent Business Overview
11.5.3 Catalent Cell and Gene Therapy Manufacturing Services Introduction
11.5.4 Catalent Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.5.5 Catalent Recent Development
11.6 WuXi AppTec
11.6.1 WuXi AppTec Company Detail
11.6.2 WuXi AppTec Business Overview
11.6.3 WuXi AppTec Cell and Gene Therapy Manufacturing Services Introduction
11.6.4 WuXi AppTec Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.6.5 WuXi AppTec Recent Development
11.7 Takara Bio Inc
11.7.1 Takara Bio Inc Company Detail
11.7.2 Takara Bio Inc Business Overview
11.7.3 Takara Bio Inc Cell and Gene Therapy Manufacturing Services Introduction
11.7.4 Takara Bio Inc Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.7.5 Takara Bio Inc Recent Development
11.8 Nikon Corporation
11.8.1 Nikon Corporation Company Detail
11.8.2 Nikon Corporation Business Overview
11.8.3 Nikon Corporation Cell and Gene Therapy Manufacturing Services Introduction
11.8.4 Nikon Corporation Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.8.5 Nikon Corporation Recent Development
11.9 FUJIFILM Holdings Corporation
11.9.1 FUJIFILM Holdings Corporation Company Detail
11.9.2 FUJIFILM Holdings Corporation Business Overview
11.9.3 FUJIFILM Holdings Corporation Cell and Gene Therapy Manufacturing Services Introduction
11.9.4 FUJIFILM Holdings Corporation Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.9.5 FUJIFILM Holdings Corporation Recent Development
11.10 F. Hoffmann-La Roche
11.10.1 F. Hoffmann-La Roche Company Detail
11.10.2 F. Hoffmann-La Roche Business Overview
11.10.3 F. Hoffmann-La Roche Cell and Gene Therapy Manufacturing Services Introduction
11.10.4 F. Hoffmann-La Roche Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.10.5 F. Hoffmann-La Roche Recent Development
11.11 Oxford Biomedica Plc
11.11.1 Oxford Biomedica Plc Company Detail
11.11.2 Oxford Biomedica Plc Business Overview
11.11.3 Oxford Biomedica Plc Cell and Gene Therapy Manufacturing Services Introduction
11.11.4 Oxford Biomedica Plc Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.11.5 Oxford Biomedica Plc Recent Development
11.12 Cell and Gene Therapy Catapult
11.12.1 Cell and Gene Therapy Catapult Company Detail
11.12.2 Cell and Gene Therapy Catapult Business Overview
11.12.3 Cell and Gene Therapy Catapult Cell and Gene Therapy Manufacturing Services Introduction
11.12.4 Cell and Gene Therapy Catapult Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.12.5 Cell and Gene Therapy Catapult Recent Development
11.13 The Discovery Labs LLC
11.13.1 The Discovery Labs LLC Company Detail
11.13.2 The Discovery Labs LLC Business Overview
11.13.3 The Discovery Labs LLC Cell and Gene Therapy Manufacturing Services Introduction
11.13.4 The Discovery Labs LLC Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.13.5 The Discovery Labs LLC Recent Development
11.14 RoslinCT
11.14.1 RoslinCT Company Detail
11.14.2 RoslinCT Business Overview
11.14.3 RoslinCT Cell and Gene Therapy Manufacturing Services Introduction
11.14.4 RoslinCT Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.14.5 RoslinCT Recent Development
11.15 JRS PHARMA
11.15.1 JRS PHARMA Company Detail
11.15.2 JRS PHARMA Business Overview
11.15.3 JRS PHARMA Cell and Gene Therapy Manufacturing Services Introduction
11.15.4 JRS PHARMA Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.15.5 JRS PHARMA Recent Development
11.16 FinVector
11.16.1 FinVector Company Detail
11.16.2 FinVector Business Overview
11.16.3 FinVector Cell and Gene Therapy Manufacturing Services Introduction
11.16.4 FinVector Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.16.5 FinVector Recent Development
11.17 ABL
11.17.1 ABL Company Detail
11.17.2 ABL Business Overview
11.17.3 ABL Cell and Gene Therapy Manufacturing Services Introduction
11.17.4 ABL Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.17.5 ABL Recent Development
11.18 Resilience
11.18.1 Resilience Company Detail
11.18.2 Resilience Business Overview
11.18.3 Resilience Cell and Gene Therapy Manufacturing Services Introduction
11.18.4 Resilience Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.18.5 Resilience Recent Development
11.19 BioCentriq
11.19.1 BioCentriq Company Detail
11.19.2 BioCentriq Business Overview
11.19.3 BioCentriq Cell and Gene Therapy Manufacturing Services Introduction
11.19.4 BioCentriq Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.19.5 BioCentriq Recent Development
11.20 Porton Biopharma Limited
11.20.1 Porton Biopharma Limited Company Detail
11.20.2 Porton Biopharma Limited Business Overview
11.20.3 Porton Biopharma Limited Cell and Gene Therapy Manufacturing Services Introduction
11.20.4 Porton Biopharma Limited Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.20.5 Porton Biopharma Limited Recent Development
11.21 Andelyn Biosciences
11.21.1 Andelyn Biosciences Company Detail
11.21.2 Andelyn Biosciences Business Overview
11.21.3 Andelyn Biosciences Cell and Gene Therapy Manufacturing Services Introduction
11.21.4 Andelyn Biosciences Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.21.5 Andelyn Biosciences Recent Development
11.22 Commercializing Living Therapies
11.22.1 Commercializing Living Therapies Company Detail
11.22.2 Commercializing Living Therapies Business Overview
11.22.3 Commercializing Living Therapies Cell and Gene Therapy Manufacturing Services Introduction
11.22.4 Commercializing Living Therapies Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.22.5 Commercializing Living Therapies Recent Development
11.23 Vibalogics
11.23.1 Vibalogics Company Detail
11.23.2 Vibalogics Business Overview
11.23.3 Vibalogics Cell and Gene Therapy Manufacturing Services Introduction
11.23.4 Vibalogics Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.23.5 Vibalogics Recent Development
11.24 Anemocyte Srl
11.24.1 Anemocyte Srl Company Detail
11.24.2 Anemocyte Srl Business Overview
11.24.3 Anemocyte Srl Cell and Gene Therapy Manufacturing Services Introduction
11.24.4 Anemocyte Srl Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.24.5 Anemocyte Srl Recent Development
11.25 ElevateBio
11.25.1 ElevateBio Company Detail
11.25.2 ElevateBio Business Overview
11.25.3 ElevateBio Cell and Gene Therapy Manufacturing Services Introduction
11.25.4 ElevateBio Revenue in Cell and Gene Therapy Manufacturing Services Business (2018-2023)
11.25.5 ElevateBio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’